Amicus Therapeutics Reports Strong Q2 2025 Growth

Amicus Therapeutics ( (FOLD) ) has released its Q2 earnings. Here is a breakdown of the information Amicus Therapeutics presented to its investors.

Amicus Therapeutics is a global biotechnology company dedicated to developing and commercializing innovative medicines for rare diseases, with a focus on Fabry and Pompe diseases.

Amicus Therapeutics reported strong financial results for the second quarter of 2025, with total revenue reaching $154.7 million, marking an 18% increase at constant exchange rates. The company continues to demonstrate robust growth driven by its key products, Galafold and Pombiliti + Opfolda.

The company’s flagship product, Galafold, achieved $128.9 million in revenue, reflecting a 12% growth at constant exchange rates, supported by new patient starts and strong compliance. Pombiliti + Opfolda saw a significant revenue increase of 58% at constant exchange rates, reaching $25.8 million, fueled by high demand and new launches in multiple countries. Despite a GAAP net loss of $24.4 million, Amicus reported a non-GAAP net income of $1.9 million for the quarter.

Amicus is making strategic advancements, including the regulatory approval of Pombiliti + Opfolda in Japan and the progression of the DMX-200 collaboration with Dimerix. The company remains optimistic about achieving GAAP profitability in the second half of 2025 and anticipates exceeding $1 billion in total revenue by 2028.

Looking ahead, Amicus Therapeutics is poised for continued growth, with management reiterating its financial guidance for 2025, expecting total revenue growth between 15% and 22%. The company is well-positioned to leverage its capabilities and address unmet patient needs in the rare disease sector.